Skip to content
Search

Latest Stories

Wockhardt UK recalls Levothyroxine Oral Solution from pharmacies

Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for Levothyroxine 100micrograms/5ml Oral Solution by Wockhardt UK Ltd.

The company is recalling specific batches of the medicine from pharmacies and wholesalers as a precautionary measure due to notification of the impurity liothyronine exceeding the specification limit.


Affected Batches:

Batch NumberExpiry DatePack SizeFirst Distributed
I5348131/03/20201 x 100ml15/04/2019
I5452231/05/20211 x 100ml03/10/2019

Liothyronine is a degradant of Levothyroxine and can be used to treat the same conditions but with a faster onset and considered to be more potent than levothyroxine. This potency difference will result in different pharmacodynamic effects for patients, the drug alert notes.

Pharmacists are advised to stop supplying the above products immediately. They should quarantine all remaining stock and return it to their original supplier using supplier’s approved process.

Company contacts for further information:

For medical Information enquiries, please contact Medical Information on 01978 661261 or email drug.safety@wockhardt.co.uk. For enquiries relating to stock returns please contact Wockhardt UK Ltd Customer Services on 01978 661261 or email customer.services@wockhardt.co.uk.

Levothyroxine 100micrograms/5ml Oral Solution - PL 29831/0495 - PIP code: 123-0051

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less